Frenchie X by VIP Clothing Limited Debuts in Kerala, Strengthening the Brand's Southern Stronghold
VMPL
New Delhi [India], June 24: VIP Clothing Limited, India's heritage innerwear company, has announced the Kerala debut of its premium men's innerwear range Frenchie X, further widening the brand's national footprint. With this latest expansion, Frenchie X collections will be available in more than 40 key multi-brand outlets and large-format stores across Kochi, Kozhikode, Thiruvananthapuram and tier-II towns, taking the line's overall presence to over 140 stores nationwide.
Launch follows successful roll-outs in Goa, Mumbai, Pune and Delhi; premium innerwear line now reaches 200 + outlets across the above mentioned cities.
"Kerala has long been one of VIP Clothing's most vibrant markets, known for its discerning consumers and strong brand loyalty," said Sunil Pathare, Chairman & Managing Director, VIP Clothing Limited. "After the encouraging response in Goa and our rapid scale-up across Mumbai, Pune and Delhi, bringing Frenchie X to Kerala was the natural next step. Shoppers here can now experience premium fabrics, futuristic waistbands and fresh colour stories--everyday essentials that combine comfort with style."
Meeting demand, online and offline: The Kerala launch is part of VIP Clothing's dual-channel growth blueprint: expanding shop-floor visibility while accelerating e-commerce and quick-commerce tie-ups. Earlier this year the company partnered with Swiggy Instamart and Zepto to deliver select Frenchie X styles in under an hour, a service that will now cover major Kerala pincodes.
Innovation-led portfolio: Frenchie X features micro-modal and cotton-elastane blends, moisture-management finishes and signature gradient waist elastics tailored for India's humid climate--attributes that resonate with Kerala's coastal consumer base. The range spans briefs, trunks, vests and gym vests, each offered in multiple colourways.
Looking ahead: "Our aim is to be wherever the modern Indian man shops--whether that's a neighbourhood MBO in Thrissur or a smartphone screen in Thiruvananthapuram," Pathare added. "Customers can expect continual design upgrades, new category entries and deeper market penetration throughout FY 25-26."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
30 minutes ago
- Business Standard
Tata Group secures top spot as India's most valuable brand: Report
Tata Group (brand value up 10 per cent to $31.6 billion) has once again secured its position as India's most valuable brand, becoming the first Indian brand to cross the $30 billion threshold, according to a report by Brand Finance. 'This historic milestone underscores India's expanding economic clout and the Tata Group's multi-sector dominance, with strategic investments in electronics, EVs, semiconductors, AI and renewables,' the report stated. The report noted that India's projected GDP growth—pegged between 6 per cent and 7 per cent for FY2025–26—bolstered by sustained capacity expansion, strong domestic demand and public–private partnerships, has positioned leading Indian brands to capitalise on global opportunities, even amid ongoing volatility. India's top 10 most valuable brands collectively registered double-digit growth in brand value, the report added. In its methodology, Brand Finance defines brand value as the net economic benefit a brand owner would achieve by licensing the brand in the open market. Brand strength refers to a brand's performance on intangible measures relative to its competitors. Ajimon Francis, managing director, Brand Finance India, said: 'India is embracing the 'Create in India' clarion call with renewed energy. Whether it's manufacturing, financial services, entertainment, holistic healing or hospitality, Brand Bharat is rewriting narratives globally. The nation's economic vibrancy, digital infrastructure and industrial expansion are turning its top brands into global beacons. In a challenging geopolitical order, India is finely balancing hard power and soft power.'
Time of India
31 minutes ago
- Time of India
Coal stock at Indian power plants rises to 61.3 MT, sufficient for 25 days of use
Coal stock at thermal power plants across the country reached an all-time high of 61.3 million tonnes, a Railways Ministry statement said. This record stockpile is possible due to mechanised loading of coal on to wagons - called silo loading, and is sufficient to meet 25 days of India's consumption. Officials said the coal stock at Indian power plants is now more than Canada's total coal production. The statement was issued after a joint review by Coal and Mines Minister , G Kishan Reddy, and Railways Minister, Ashwini Vaishnaw. The Ministers focused on expanding silo infrastructure across key coalfields. Silo loading refers to the mechanized process of loading bulk materials (like coal) into railway wagons directly from a storage silo, rather than using conventional methods like front-end loaders or manual shoveling. It ensures uniform coal sizing, eliminates complaints related to oversized boulders from power plants, reduces damage to wagons, and enables reliable operations unaffected by adverse weather conditions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Accounting Automation Software Might Help You To Earn More Accounting Automation Software | Search ads Undo 'There has been a notable increase in the share of coal loaded through silos—from 18.8% in 2022–23 to 29% in 2025–26 (till date)—demonstrating a clear and sustained push towards improving coal logistics,' the statement added.
Mint
41 minutes ago
- Mint
India boost to pharma & medtech R&D with ₹5,000 cr portal
New Delhi: The Department of Pharmaceuticals has launched an online portal for a ₹ 5,000-crore scheme it says will support innovation in pharma and medical technology. PRIP, or the Promotion of Research and Innovation in Pharma MedTech Sector, promises to make it easier to submit applications to develop novel technologies in medicine, including medical devices and drugs for communicable, non-communicable diseases and rare disease. The government is concerned about the tiny levels of domestic R&D spending, compared with many other nations, despite India being a global leader in generic drug production. While the US and China spend $60 billion and $20 billion on pharmaceutical R&D respectively, India's expenditure is only around $3 billion. PRIP aims to bridge this gap and foster a culture of research and innovation in the pharma and medtech industry. The scheme has two main components. First, strengthening research infrastructure: This involves setting up Centres of Excellence (CoEs) in the seven existing National Institutes of Pharmaceutical Education & Research (NIPERs). Second, Promoting Research in Pharma & MedTech: This component offers direct financial assistance to companies and projects for both in-house R&D and academic collaborations. It covers six priority areas, including drug discovery and development, medical devices, stem cell therapy, medicines for rare diseases and treatment for drug-resistant patients. "With the PRIP portal now live, the government is making it simple for pharma companies, medtech firms, and even startups to register and elevate their research and development capabilities," explained an official. As planned under the scheme, bigger companies can seek funding of up to ₹ 125 crore while startups can secure up to ₹ 1 crore over a period of five years, based on their milestones, the official said. India's pharmaceutical market is a global force, valued at $50 billion. While domestic consumption stands at $23.5 billion, exports contribute a significant $26.5 billion. India is the world's third-largest pharmaceutical market by volume and 14th by value of production. Over half its exports reach highly developed markets like the US, EU, and Japan, which have a high threshold on quality. Sheetal Arora, promoter and CEO of Mankind Pharma, emphasized the transformative potential of the PRIP scheme. "The new PRIP portal is a game-changer for Indian pharma. This ₹ 5,000-crore investment is exactly the boost we need as we're on the verge of massive growth. India already leads the world in generic medicines, providing 20% of the global supply. But PRIP helps us shift towards innovation, potentially bringing in another ₹ 17,000 crore for R&D by FY28. This will truly sharpen our competitive edge. The timing couldn't be better. With many major drugs losing patent protection by 2030, companies that invest in new molecules and top-tier research now will be future leaders. What's most exciting is that PRIP supports both innovation and affordable healthcare.' Arora added that PRIP supports both innovation and affordable healthcare. 'This perfectly fits India's goal of being a global innovation hub while also making medicines accessible worldwide. PRIP isn't just about money; it's about empowering Indian pharma to build a strong, self-reliant future where innovation benefits everyone,' she said.
